0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Xerostomia Drug"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Global Xerostomia Therapeutics Market Report 2024 - Product Thumbnail Image

Global Xerostomia Therapeutics Market Report 2024

  • Report
  • July 2024
  • 175 Pages
  • Global
From
EUR$5,000USDGBP
From
EUR$5,600USDGBP
From
EUR$2,999USDGBP
Xerostomia - Pipeline Insight, 2024 - Product Thumbnail Image

Xerostomia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
EUR$1,250USDGBP
From
EUR$4,150USDGBP
From
EUR$7,950USDGBP
Xerostomia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Xerostomia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
EUR$3,950USDGBP
From
EUR$4,500USDGBP
From
EUR$4,750USDGBP
From
EUR$2,000USDGBP
  • 14 Results (Page 1 of 1)
Loading Indicator

Xerostomia Drug is a type of drug used to treat dry mouth, a condition caused by a decrease in saliva production. Xerostomia is a common symptom of immune disorders, such as Sjogren's Syndrome, HIV/AIDS, and lupus. Xerostomia drugs are designed to increase saliva production and reduce the discomfort associated with dry mouth. These drugs can be taken orally, applied topically, or administered through a nasal spray. Commonly used xerostomia drugs include pilocarpine, cevimeline, and bromhexine. The xerostomia drug market is a rapidly growing segment of the immune disorder drug market. It is driven by the increasing prevalence of immune disorders, as well as the development of new drugs to treat dry mouth. Companies in the xerostomia drug market include GlaxoSmithKline, Novartis, Merck, Pfizer, and Sun Pharmaceuticals. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more